Macrocure (NASDAQ:MCUR) & Mallinckrodt PLC (MNK) Head-To-Head Survey

Macrocure (NASDAQ: MCUR) and Mallinckrodt PLC (NYSE:MNK) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitabiliy.

Profitability

This table compares Macrocure and Mallinckrodt PLC’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Macrocure	N/A	-24.50%	-22.85%
Mallinckrodt PLC	16.01%	16.33%	5.48%

Volatility & Risk

Macrocure has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Mallinckrodt PLC has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Macrocure and Mallinckrodt PLC, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Macrocure	0	0	0	0	N/A
Mallinckrodt PLC	0	2	15	0	2.88

Mallinckrodt PLC has a consensus target price of $76.38, indicating a potential upside of 70.23%. Given Mallinckrodt PLC’s higher probable upside, analysts plainly believe Mallinckrodt PLC is more favorable than Macrocure.

Insider and Institutional Ownership

2.8% of Macrocure shares are owned by institutional investors. Comparatively, 96.4% of Mallinckrodt PLC shares are owned by institutional investors. 0.8% of Mallinckrodt PLC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Macrocure and Mallinckrodt PLC’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Macrocure	N/A	N/A	N/A	($1.91)	-0.79
Mallinckrodt PLC	$3.31 billion	1.35	$744.30 million	$5.28	8.50

Mallinckrodt PLC has higher revenue and earnings than Macrocure. Macrocure is trading at a lower price-to-earnings ratio than Mallinckrodt PLC, indicating that it is currently the more affordable of the two stocks.

Summary

Mallinckrodt PLC beats Macrocure on 10 of the 10 factors compared between the two stocks.

Macrocure Company Profile

Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body’s natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.

Mallinckrodt PLC Company Profile

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.